Track Boston Scientific Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Boston Scientific Corporation BSX · Stock Open Boston Scientific Corporation in new tab

44.34 USD
P/E
18.71
EPS
2.37
P/B
2.51
ROE
14.12
Beta
0.59
Target Price
49.60 USD
Boston Scientific Corporation logo

Boston Scientific Corporation

🧾 Earnings Recap – Q3 2026

Boston Scientific fell 5.8% after a sharp Q3 miss and a weaker outlook: organic sales grew 1.5%, below the company’s 3%–5% guide, and Q4 guidance calls for an organic revenue decline of 1%–3%. Beyond the cyber incident’s near-term impact, investors face intensifying EP competition, pressure on WATCHMAN, and management’s warning that 2027 sales and adjusted EPS could be difficult to grow.

  • Q3 adjusted EPS was $0.73, versus company guidance of $0.80–$0.82; management estimated the cyber incident reduced sales growth by about 300 basis points and adjusted EPS by $0.07.
  • For Q4, the company expects organic revenue to decline 1%–3% and adjusted EPS of $0.77–$0.79, citing cyber-related effects, inventory replenishment after elevated customer orders, EP share pressure, and tougher China pricing.
  • Full-year 2026 guidance is 4% organic revenue growth and adjusted EPS of $3.16–$3.18. Management expects 2027 to be a trough year and says sales and adjusted EPS may be challenging to grow, excluding Penumbra.
  • Performance was uneven: neuromodulation sales grew 13%, while urology declined 3%; U.S. operational sales were flat and Asia Pacific declined 1%.
  • Management expects new launches and restructuring actions to support stabilization and a return to growth in 2028, but that recovery is prospective rather than a near-term offset to the outlook.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 3, 2027
P/E18.71
EPS2.37
Book Value17.68
Price to Book2.51
Debt/Equity46.20
% Insiders0.638%
Growth
Revenue Growth0.01%
Earnings Growth-0.22%
Estimates
Forward P/E14.16
Forward EPS3.13
Target Mean Price49.60

DCF valuation

Model fair value for Boston Scientific Corporation (BSX)
Result
Sign in to run the valuation for BSX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
28 analysts · consensus Buy · mean target 49.60 USD (low 41.00, high 60.00) · as of 15 Nov 2026
Low 41.00
Mean 49.60
High 60.00
Price 44.34
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Boston Scientific Corporation Logo Boston Scientific Corporation Analysis (BSX)

Is Boston Scientific Corporation a good investment? Boston Scientific Corporation (BSX) is currently trading at 44.34 USD. Market analysts have a consensus price target of 49.60 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 18.71. This valuation is generally in line with the broader market.

Earnings Schedule: Boston Scientific Corporation is expected to release its next earnings report on Feb. 3, 2027. The market consensus estimate for Forward EPS is 3.13.

Investor FAQ

Does Boston Scientific Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Boston Scientific Corporation?

Boston Scientific Corporation is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 3, 2027. The company currently has a trailing EPS of 2.37.

Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Exchange Ticker
US1011371077
BSX.SG
BSX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Dec. 1, 1998 2:1
Nov. 6, 2003 2:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion